PRLD
Prelude Therapeutics
$3.89
+$0.06 (+1.57%)Jul 27, 2026
Key metrics
The numbers that frame PRLD today
- Market cap
- $309.82M
- P/E (TTM)
- -4.0
- EV / FCF
- -6.9
- Gross margin
- 100%
- EV / Sales
- 18.1
- ROIC
- -117.9%
- Div yield
- 0%
- Debt / equity
- 0.3
- 52wk Low
- $0.75
- 52wk High
- $5.68
Growth
Revenue and earnings trend for PRLD
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about PRLD
Is Prelude Therapeutics a good buy?
Yes. Prelude Therapeutics has excellent momentum, and it outweighs the poor quality here. Growth looks excellent, which supports the long-term business case. We think Prelude Therapeutics is selling at a very high price, which cuts against the buy case.
What is the market capitalization of PRLD?
Prelude Therapeutics's market capitalization is $309.82M.
What is the P/E ratio for PRLD stock?
Prelude Therapeutics's current P/E ratio is -4.
What is the 52-week high for PRLD stock?
The 52-week high for Prelude Therapeutics is $5.68. The current close of $3.89 is 31.5% below that high.
What is the 52-week low for PRLD stock?
The 52-week low for Prelude Therapeutics is $0.75. The current close of $3.89 is 418.7% above that low.
Does PRLD stock pay dividends?
Prelude Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for PRLD?
Prelude Therapeutics's Debt / Equity ratio is 0.29.